Phospho-EPOR (Tyr368) Antibody

What is Phospho-EPOR (Tyr368) Antibody and what specifically does it recognize?

Phospho-EPOR (Tyr368) Antibody is a polyclonal antibody that specifically detects endogenous levels of the Erythropoietin Receptor (EPOR) protein only when phosphorylated at tyrosine residue 368. The antibody binds to the phosphorylated sequence DTyLV, with the lowercase "y" representing the phosphorylated tyrosine residue . This antibody is typically raised in rabbits using a synthesized peptide derived from human EPOR around the phosphorylation site of Tyr368 (amino acid range 341-390) . The high specificity of this antibody enables researchers to monitor EPOR activation status in response to erythropoietin stimulation and other experimental conditions.

What are the validated applications for Phospho-EPOR (Tyr368) Antibody?

Phospho-EPOR (Tyr368) Antibody is validated for multiple research applications:

The antibody has not been fully validated for other applications such as immunohistochemistry or flow cytometry. Researchers should perform their own validation when adapting the antibody to other techniques .

How should Phospho-EPOR (Tyr368) Antibody be stored to maintain optimal activity?

For optimal antibody performance, the following storage conditions are recommended:

• Short-term storage (up to 6 months): 2-8°C (refrigerated)

• Long-term storage: -15°C to -25°C (do not store below -25°C)

• The antibody is typically supplied in liquid form in PBS containing 50% glycerol, 0.5% BSA, and 0.02% sodium azide

• Avoid repeated freeze-thaw cycles to prevent protein degradation and loss of activity

• For prolonged stability, aliquot the antibody into working volumes before freezing

What are the recommended controls when using Phospho-EPOR (Tyr368) Antibody in experimental systems?

When designing experiments with Phospho-EPOR (Tyr368) Antibody, implementing the following controls is essential:

• Positive control: EPO-stimulated cells known to express EPOR (e.g., UT7epo cell line)

• Negative control: Unstimulated cells or cells with inhibited JAK2 activity

• Blocking peptide control: Using the specific phospho-peptide (available as product AF3211-BP or similar) to confirm antibody specificity

• Phosphatase treatment control: Treating some samples with phosphatase to demonstrate phospho-specificity

• siRNA/knockout control: Cells with EPOR knockdown/knockout to verify specificity

Blocking peptide controls are particularly valuable when non-specific binding is a concern. The synthetic peptide contains the epitope recognized by the antibody and can be used to neutralize the antibody before application. Comparing staining patterns between blocked and unblocked antibody clearly distinguishes specific from non-specific binding .

How can I optimize Western blot protocols using Phospho-EPOR (Tyr368) Antibody?

Optimizing Western blot protocols for Phospho-EPOR (Tyr368) detection requires careful attention to several critical factors:

• Sample preparation:

  • Rapidly lyse cells in buffer containing phosphatase inhibitors

  • Use fresh tissue samples or flash-freeze immediately

  • Maintain samples at 4°C throughout processing

• Gel electrophoresis parameters:

  • Use 8-10% polyacrylamide gels for optimal resolution of the 55kD EPOR protein

  • Load sufficient protein (30-50μg total protein per lane)

  • Include molecular weight markers with standards near 55kD

• Transfer and blocking:

  • Use PVDF membrane (preferred over nitrocellulose for phosphoproteins)

  • Block with 5% BSA in TBST rather than milk (milk contains phosphoproteins)

  • Consider overnight transfer at low voltage for large proteins

• Antibody incubation:

  • Begin with 1:1000 dilution in 5% BSA/TBST and adjust if needed

  • Incubate primary antibody overnight at 4°C

  • Wash thoroughly (4-5 times, 5 minutes each) between antibody steps

• Detection optimization:

  • Use enhanced chemiluminescence detection systems

  • Consider signal enhancement systems for low abundance phosphoproteins

  • Avoid overexposure which may obscure differences in phosphorylation levels

What is the biological significance of EPOR phosphorylation at Tyr368 compared to other phosphorylation sites?

EPOR phosphorylation at Tyr368 represents a critical regulatory event in the EPO signaling cascade:

• Upon EPO stimulation, JAK2 phosphorylates multiple tyrosine residues on EPOR, including Tyr368

• Phosphorylated Tyr368 contributes to the recruitment of downstream signaling molecules

• EPOR contains multiple phosphorylation sites with distinct functions: Tyr426 is required for SOCS3 and PTPN11 binding, while Tyr454 is necessary for PTPN6 interaction

• The Tyr454/Tyr456 motif is the preferred binding site for certain signaling molecules

• Phosphorylation at Tyr368 appears to be particularly important for sustaining EPO-induced activation of multiple pathways including ERK1/2, AKT, and STAT5

The specific phosphorylation pattern on EPOR determines the quality and duration of downstream signaling events, with Tyr368 playing a distinctive role in this signaling network.

How can I troubleshoot non-specific binding when using Phospho-EPOR (Tyr368) Antibody?

When encountering non-specific binding issues with Phospho-EPOR (Tyr368) Antibody, implement these systematic troubleshooting approaches:

• Verify specificity with blocking peptides:

  • Perform parallel experiments with antibody pre-incubated with blocking peptide

  • Compare staining patterns to identify true signal versus background

  • Use both phosphorylated and non-phosphorylated peptides for comparison

• Optimize antibody concentration:

  • Titrate antibody concentration to find optimal signal-to-noise ratio

  • Generally start with manufacturer's recommended dilution (1:500-1:2000 for WB)

  • Reduce concentration if background is high

• Improve blocking and washing:

  • Use 5% BSA rather than milk for phospho-specific antibodies

  • Extend blocking time to 2 hours at room temperature

  • Increase number and duration of wash steps

  • Add 0.1% Tween-20 to wash buffers to reduce non-specific binding

• Sample preparation refinements:

  • Ensure complete phosphatase inhibition during lysate preparation

  • Consider immunoprecipitation to enrich for EPOR before Western blotting

  • Use freshly prepared samples to preserve phosphorylation state

• Control for phosphorylation specificity:

  • Include λ-phosphatase-treated control samples

  • Use cells with known phosphorylation status (±EPO stimulation)

What experimental models are most appropriate for studying EPOR Tyr368 phosphorylation?

The choice of experimental model is critical for studying EPOR Tyr368 phosphorylation:

• Cell line models:

  • EPO-dependent human erythroid progenitor UT7epo cell line is a validated model

  • UT7epo provides sufficient cell numbers for effective PTM proteomics analysis

  • Other models include TF-1 cells and BaF3 cells stably transfected with EPOR

• Primary cell cultures:

  • CD34+ hematopoietic progenitor cells induced toward erythroid differentiation

  • Primary erythroblasts at different maturation stages

  • Bone marrow-derived erythroid progenitors

• Tissue samples:

  • Bone marrow biopsies (with appropriate preparation)

  • Fetal liver during active erythropoiesis

• Model considerations:

  • Expression levels vary by cell type: EPOR-F isoform is abundant in EPO-dependent erythroleukemia cells and late-stage erythroid progenitors, while EPOR-S and EPOR-T isoforms predominate in bone marrow and early-stage erythroid progenitor cells

  • Cellular localization should be considered: EPOR is primarily localized to the cell membrane as a single-pass type I membrane protein, though some isoforms (EPOR-S) are secreted

How can Phospho-EPOR (Tyr368) Antibody be used to investigate EPO-induced signaling pathways?

The Phospho-EPOR (Tyr368) Antibody serves as a valuable tool for dissecting EPO signaling:

• Phosphorylation kinetics analysis:

  • Perform time-course experiments following EPO stimulation

  • Monitor Tyr368 phosphorylation at intervals (0, 5, 15, 30, 60 minutes)

  • Compare with phosphorylation kinetics of downstream effectors (STAT5, ERK1/2, AKT)

• Pathway interaction studies:

  • Use in combination with phospho-specific antibodies for JAK2, STAT5, ERK1/2, and AKT

  • Perform sequential immunoprecipitation to identify protein complexes

  • Correlate EPOR phosphorylation with activation of downstream signaling molecules

• Integration with phospho-PTM proteomics:

  • Combine with liquid chromatography tandem mass spectrometry (LC-MS/MS)

  • Identify novel EPO-modulated pY-modified kinases and phosphatases

  • Example: This approach identified 17 novel EPO-modulated pY-modified kinases and 5 novel EPO-modulated phosphatases

• Phosphatase regulation studies:

  • Investigate regulators like PTPN18 that sustain EPO-induced activation

  • PTPN18 affects EPO-induced activation of ERK1/2, AKT, STAT5, and JAK2 through its EPO-modulated pY389 site

  • Examine how phosphatases affect high molecular weight EPOR forms and the phosphorylation of associated adaptor proteins like RHEX-pY141

What are the key technical specifications of Phospho-EPOR (Tyr368) Antibody?

How can I validate the specificity of the Phospho-EPOR (Tyr368) Antibody in my experimental system?

Thorough validation of antibody specificity is crucial for reliable experimental outcomes:

• Phosphorylation-state verification:

  • Compare signal between EPO-stimulated and unstimulated samples

  • Treat duplicate samples with λ-phosphatase to remove phosphorylation

  • Verify loss of signal in dephosphorylated samples

• Blocking peptide competition:

  • Pre-incubate antibody with phospho-Tyr368 peptide before application

  • Compare signal with and without blocking peptide

  • Specific signals should be eliminated by peptide competition

• Genetic approaches:

  • Use EPOR knockout cells as negative controls

  • Generate EPOR-Y368F mutant (non-phosphorylatable) for comparison

  • Verify loss of signal in mutant samples

• Orthogonal detection methods:

  • Confirm phosphorylation status using mass spectrometry

  • Use alternative phospho-specific antibodies if available

  • Perform functional assays correlating with phosphorylation status

• Cross-reactivity assessment:

  • Test against related receptors (e.g., growth hormone receptor)

  • Evaluate potential cross-reactivity with other phospho-tyrosine sites

  • Perform peptide array analysis to confirm epitope specificity

How can Phospho-EPOR (Tyr368) Antibody contribute to myeloproliferative neoplasm research?

Phospho-EPOR (Tyr368) Antibody offers significant potential in myeloproliferative neoplasm research:

• Diagnostic biomarker exploration:

  • Evaluate EPOR-Tyr368 phosphorylation levels in patient samples

  • Correlate with disease progression and treatment response

  • Investigate as a potential diagnostic or prognostic marker

• Therapeutic target validation:

  • Screen compounds that modulate EPOR phosphorylation at Tyr368

  • Evaluate phosphatases like PTPN18 that promote EPO-dependent hematopoietic cell growth as potential druggable targets

  • Monitor treatment efficacy through phosphorylation status

• Signaling pathway elucidation:

  • Characterize aberrant signaling in myeloproliferative disorders

  • Identify novel regulators of EPOR phosphorylation

  • Map cross-talk between EPOR and other pathways in disease states

• Functional consequence analysis:

  • Correlate Tyr368 phosphorylation with cellular outcomes

  • Examine differences between normal and malignant cells

  • Investigate resistance mechanisms to existing therapies

• Combination therapy development:

  • Identify synergistic targets based on phosphorylation status

  • Develop rational drug combinations targeting different aspects of the pathway

  • Monitor pathway modulation during treatment

What are the considerations for multiplexing Phospho-EPOR (Tyr368) Antibody with other phospho-specific antibodies?

When designing multiplex experiments with Phospho-EPOR (Tyr368) Antibody:

• Antibody compatibility assessment:

  • Verify primary antibodies are from different host species

  • If using same species, employ sequential detection methods

  • Test for cross-reactivity between secondary antibodies

• Signal separation strategies:

  • Use spectrally distinct fluorophores for immunofluorescence

  • Consider sequential blotting for Western blots

  • Implement appropriate controls for each antibody

• Sample preparation optimization:

  • Ensure preservation of all phosphorylation sites of interest

  • Use broad-spectrum phosphatase inhibitors

  • Optimize lysis conditions to maintain native protein conformation

• Data analysis refinement:

  • Account for potential signal overlap

  • Normalize phospho-signals to total protein levels

  • Consider relative stoichiometry of different phosphorylation events

• Temporal dynamics consideration:

  • Different phosphorylation sites may have distinct kinetics

  • Design time-course experiments to capture all relevant events

  • Correlate phosphorylation patterns with functional outcomes